Autoantibodies to Abl and Bcr proteins

Leukemia. 2000 Sep;14(9):1661-6. doi: 10.1038/sj.leu.2401870.

Abstract

Formation of an aberrant, chimeric Bcr-Abl protein is the hallmark of Philadelphia (Ph) chromosome-positive leukemias. The Bcr-Abl protein, as well as its normal cellular counterparts--Abl and Bcr--are intracellular molecules with postulated roles in a variety of critical biologic functions. In this study, we demonstrate the existence of autoantibodies against these proteins. Plasma from 18 of 31 individuals (58%), including 14 of 20 Ph-positive CML patients (70%), two of four normal volunteers (50%), and two of seven patients with Ph-negative leukemia (29%) recognized p210Bcr-Abl when used in immunoprecipitation followed by immunoblotting experiments. In all 18 patients, plasma was able to recognize baculovirus-expressed Abl protein; in four patients, recognition of baculovirus-expressed Bcr protein was also demonstrated. These observations suggest that a humoral immune response to p210Bcr-Abl is discernible in both Ph-positive and -negative leukemias and in healthy individuals, and is most likely due to autoantibodies which recognize normal Abl and, to a lesser extent, normal Bcr proteins.

MeSH terms

  • Adult
  • Aged
  • Autoantibodies / blood
  • Autoantibodies / immunology*
  • Female
  • Fusion Proteins, bcr-abl / immunology*
  • Humans
  • K562 Cells
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology*
  • Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / immunology
  • Male
  • Middle Aged
  • Oncogene Proteins / immunology
  • Philadelphia Chromosome
  • Protein-Tyrosine Kinases*
  • Proto-Oncogene Proteins c-abl / immunology
  • Proto-Oncogene Proteins c-bcr
  • Proto-Oncogene Proteins*

Substances

  • Autoantibodies
  • Oncogene Proteins
  • Proto-Oncogene Proteins
  • Protein-Tyrosine Kinases
  • Fusion Proteins, bcr-abl
  • Proto-Oncogene Proteins c-abl
  • BCR protein, human
  • Proto-Oncogene Proteins c-bcr